Clinical trials: Low and Intermediate Risk Prostate Cancer
Prostate Cancer
Focal Laser Ablation for the Treatment of Focal Low-Intermediate Risk Prostate Cancer
Short-term Efficacy of Transperineal Laser Ablation (TPLA) with Image Fusion and Multi-parametric (mpMRI) Follow-up in Focal Low-intermediate Risk Prostate Cancer. It is an interventional pilot study.
- Trial name
- NCT04045756
- Testing
- Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Rome Tor Vergata
Prostate Adenocarcinoma
Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer
The LDR BURST trial will compare the side effects of two radiotherapy treatments for men with localised prostate cancer. The first treatment is 4D low dose rate brachytherapy where small radioactive seeds are inserted into the…
- Trial name
- LDR BURST (NCT07210502)
- Testing
- 4D Low Dose Rate Prostate Brachytherapy, Ultra-hypofractionated Radiotherapy
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Prostate Cancer
LDR Brachytherapy Versus SBRT for Low and Intermediate Risk Prostate Cancer Patients
The aim of this trial is to find out if there are any differences in the profiles of acute and late adverse effects among men with low and intermediate risk prostate cancer treated either with low dose-rate brachytherapy or…
- Trial name
- BRAVEROBO (NCT02895854)
- Testing
- Hypofractionated RT 5 x 7,25 Gy, LDR-brachytherapy with I125 seeds
- Where
- Finland
- Volunteers
- 44 people
- Sponsor
- Kuopio University Hospital
Prostate Cancer, Ultrasound Therapy
Evaluation of HIFU in TREATMENT OF LOCALIZED PROSTATE CANCER and OF RECURRENCE AFTER RADIOTHERAPY
to compare the efficacy of HIFU treatment with standard treatment in two situations: 1. as first-line cancer treatment, HIFU is compared to radical prostatectomy. 2.
- Trial name
- HIFI (NCT04307056)
- Testing
- Radical Prostatectomy, High Intensity Focused Ultrasound (HIFU) Treatment
- Where
- 49 sites in France, Guadeloupe
- Volunteers
- 3,862 people
- Sponsor
- Association Francaise d'Urologie
Prostate Cancer
Prospective Evaluation of Mp-MRI, MR-guided Biopsy, and Molecular Markers for Active Surveillance of Prostate Cancer
Active Surveillance (AS) is a treatment option in patients with favorable risk prostate cancer. According to the current guidelines patients are monitored by prostate specific antigen (PSA) testing (every 3 months) and regular…
- Trial name
- PROMM-AS (NCT03979573)
- Testing
- Multiparametric MRI, Radiomics, MR-guided Biopsy
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Prostate Cancer (Adenocarcinoma), Low and Intermediate Risk Prostate Cancer
Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness
This clinical research study is intended to show that Micro-Ultrasound Guided Focal Laser Ablation (MicroUSgFLA) is a safe procedure that can significantly postpone or eliminate the need for patients with intermediate-Risk…
- Trial name
- MicroUSgFLA (NCT07339943)
- Testing
- 6 month, prospective, interventional single-arm safety and effectiveness study, The TRANBERG|CLS Thermal therapy
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer, Low and Intermediate Risk Prostate Cancer
MRI Guided Focal Laser Ablation of Prostate Cancer
This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate.
- Trial name
- MRgFLA (NCT03650595)
- Testing
- The TRANBERGCLS|Thermal Therapy
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer
Patients with primary low and intermediate risk prostate cancer (PCa) for whom radical prostatectomy are indicated, will be invited to participate to the present study.
- Trial name
- NCT05073653
- Testing
- 68Ga-PSMA PET/CT, 68Ga-GRP PET/CT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xiangya Hospital of Central South University
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Prostate Cancer
MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients
Radiation therapy plays an important role in the management of prostate cancer. In recent years it has become evident that higher doses of radiation are required to optimize disease control.
- Trial name
- MARS (NCT02623933)
- Testing
- MRI assisted focal boost with HDR monotherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Low Risk Prostate Cancer, Intermediate Risk Prostate Cancer
Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer
This prospective study assess the effectiveness and safety of hypofractionated proton radiotherapy in the treatment of intermediate and low risk prostate cancer.
- Trial name
- NCT03740191
- Testing
- EPIC questionnaire, kV x-ray images, Conebeam CT
- Where
- Austria
- Volunteers
- 5 people
- Sponsor
- EBG MedAustron GmbH
Prostate Cancer
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients…
- Trial name
- NCT04264208
- Testing
- 68-Ga RM2., 68-Ga PSMA11, PET/MRI
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Andrei Iagaru
Prostatic Adenocarcinoma
Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid
The present randomized, open, multicentric Phase II trial, in parallel groups with two arms of treatment, compares the treatment A, moderate hypofractionated radiotherapy of 62Gy, to treatment B, stereotactic irradiation of 37.5…
- Trial name
- RPAH2 (NCT02361515)
- Testing
- Moderate hypofractionated radiotherapy, Stereotactic radiotherapy
- Where
- 7 sites in France
- Volunteers
- 96 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy
RATIONALE: Diagnostic procedures, such as MRI, may help measure oxygen levels in tumor cells. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00963300
- Testing
- blood-oxygen-level-dependent functional magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopic imaging
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer
A prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease.
- Trial name
- MRSI+RRP (NCT01780701)
- Testing
- Magnetic Resonance Spectroscopy Imaging with rectal probe
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- OHSU Knight Cancer Institute
Prostatic Neoplasms
Prostate Accurately Targeted Radiotherapy Investigation of Overall Treatment Time
The purpose of this study is to compare the toxicity of two new radiation schedules for the treatment of prostate cancer. Patients will be randomized to receive 5 treatments delivered every other day over 11 days, or once per…
- Trial name
- PATRIOT (NCT01423474)
- Testing
- Image-guided radiotherapy
- Where
- 3 sites in Canada
- Volunteers
- 152 people
- Sponsor
- CancerCare Manitoba
Prostate Cancer, Prostatic Cancer
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.
- Conditions
- Prostate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms
- Trial name
- NCT00643617
- Testing
- CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk
- Where
- 18 sites in United States
- Volunteers
- 307 people
- Sponsor
- Accuray Incorporated